Trial Profile
A phase II Study of AT9283 in Patients with Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs AT 9283 (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 27 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Apr 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 15 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov